Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LGC forms "personalised" drug testing deal:

This article was originally published in Clinica

Executive Summary

UK genetic testing firm LGC has issued a testing licence to Orchid BioSciences for the key DNA variant in the CYP2D6 gene, which controls a drug metabolising enzyme in the human liver. Individuals with the gene mutation, around 6% of the Caucasian population, cannot correctly metabolise around 20% of currently prescribed medications, says Teddington, Middlesex-based LGC. Testing for the mutation may help predict a patient's response to various drugs and help them avoid serious adverse reactions.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT067021

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel